EGFR and colorectal carcinoma: Thus, we evaluated the IC50 of commonly used and targeted drugs for CRC in the high- and low-risk groups and found that the high-risk group was more sensitive to the first-line drugs cisplatin and oxaliplatin, DNA-repair-related PARP inhibitors (Rucaparib, FH535), and EGFR inhibitors (Erlotinib).